CNBC published a news item on Thursday April 4, expressing the challenge that superbugs, MRSA and CRE in particular, pose to our health care system. Dr. Cesar Arias, an associate professor of infectious diseases at the University of Texas Health Science Center, calls it a “crisis situation” and goes on to note that, “”The World Health Organization says this is one of the top three health threats to the world in this century, and I can’t argue with that.”
Biocidium’s K-yur 001 antimicrobial has a proven CRE kill rate of 99.9999% and we are very excited about the possibilities of our additive and products to help fight this growing threat.
Two other passages worth noting, which demonstrate just how significant of an issue it is:
“These bacteria not only take a tragic toll on human life but involve major costs. A new study by MPHonline.org reports that superbugs are responsible for $20 billion in excess health care costs in the U.S propranolol pills online. annually, as well as $35 billion in lost wages and other societal costs from the almost eight million days that infected patients spend in the hospital.”
“The curtailment comes as MRSA kills an estimated 19,000 people every year in the U.S., compared with the 17,000 who die from AIDS, according to the Centers for Disease Control.”
Read the full story by Mark Koba, Senior Editor, CNBC at: http://www.cnbc.com/id/100615929